Emily Jones

Dr. Emily Jones

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2021 in Genes
Verified
Journal Article
Open access
PDF file
EJEmily Jones
Emily Jones
RSRégis Stentz
Régis Stentz
Andrea TelatinAndrea Telatin
Andrea Telatin
GSGeorge M. Savva
George M. Savva
CBCatherine Booth
Catherine Booth
SCSimon Carding
Simon Carding
The gastrointestinal tract harbors the gut microbiota, structural alterations of which (dysbiosis) are linked with an increase in gut permeability (“leaky gut”), enabling luminal antigens and bacterial products such as nanosized bacterial extracellular vesicles (BEVs) to access the circulatory system. Blood-derived BEVs contain various cargoes and may be useful biomarkers for diagnosis and monitoring of disease status and relapse in conditions such as inflammatory bowel disease (IBD). To progress this concept, we developed a rapid, cost-effective protocol to isolate BEV-associated DNA and used 16S rRNA gene sequencing to identify bacterial origins of the blood microbiome of healthy individuals and patients with Crohn’s disease and ulcerative colitis. The 16S rRNA gene sequencing successfully identified the origin of plasma-derived BEV DNA. The analysis showed that the blood microbiota richness, diversity, or composition in IBD, healthy control, and protocol control groups were not significantly distinct, highlighting the issue of ‘kit-ome’ contamination in low-biomass studies. Our pilot study provides the basis for undertaking larger studies to determine the potential use of blood microbiota profiling as a diagnostic aid in IBD.

1 October 2015 in Microbes and Infection
Verified
Journal Article
Closed access
CWCaroline M. Weight
Caroline M. Weight
EJEmily Jones
Emily Jones
NHNikki Horn
Nikki Horn
NWNikolaus Wellner
Nikolaus Wellner
SCSimon Carding
Simon Carding

11 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CWCarrie Wemyss
Carrie Wemyss
EJEmily Jones
Emily Jones
RSRégis Stentz
Régis Stentz
SCSimon Carding
Simon Carding
Acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) remain significant challenges in haematological oncology. This review examines the pathophysiology, classification, and risk stratification of these aggressive malignancies, emphasising their impact on treatment strategies and prognosis. We discuss current standard-of-care treatments, including chemotherapy regimens and targeted therapies, while addressing the associated adverse effects and hypersensitivity reactions. Delving into the metabolic characteristics and vulnerabilities of leukaemia cells, the review highlights the key differences between lymphoid and myeloid leukaemia and how metabolic insights can be utilised for therapeutic purposes, with special focus on asparaginase therapy and its potential for improvement in both ALL and AML treatment. The review conveys the importance of personalised medicine approaches based on individual metabolic profiles and the challenges posed by metabolic heterogeneity and plasticity in leukaemia cells. Combining molecular and metabolic profiling can enhance and refine treatment strategies for acute leukaemia, potentially improving patient outcomes and quality of life. However, integrating these into routine clinical practice requires overcoming various practical, technical, and logistical issues.

19 November 2025 in Extracellular Vesicles and Circulating Nucleic Acids
Verified
Journal Article
Open access
PDF file
EJEmily Jones
Emily Jones
APAimee Parker
Aimee Parker
RJRokas Juodeikis
Rokas Juodeikis
LBL. Ashley Blackshaw
L. Ashley Blackshaw
ABArlaine Brion
Arlaine Brion
SCSimon Carding
Simon Carding
Aim: This study aims to investigate how the gut microbiota communicates with the host via bacterial extracellular vesicles (BEVs), given that direct contact between microbes and the healthy intestinal epithelium is prevented by a sterile mucin gel layer. Understanding these indirect interactions is critical because the specific pathways and mediators of microbiota-host interactions are incompletely understood. Tracking BEVs in vivo however is particularly challenging due to their nanoscale size and complex molecular composition. Methods: To address these challenges, we developed a highly sensitive Nanoluciferase (NanoLuc) system for luminescence-based detection of BEVs produced by the model human commensal bacterium Bacteroides thetaiotaomicron. This approach was evaluated in germ-free and specific-pathogen-free mice, with comparisons between administration routes demonstrating the advantages of this system for in vivo BEV labelling over conventional lipophilic dyes. Results: We report, for the first time, that BEVs endogenously produced in the gastrointestinal tract (GIT) of mice can deliver bioactive NanoLuc protein to multiple organ tissues, including the central nervous system. Our findings establish that naturally occurring BEVs in the GIT are capable of traversing multiple host barriers, including the intestinal epithelium, vascular endothelium, and the blood-brain-barrier, to access tissues such as the brain and eyes. Conclusion: These findings advance our understanding of BEV-mediated microbe-host interactions and demonstrate the potential of BEVs as vehicles for long-distance delivery of bioactive therapeutics.

1 September 2023 in Biomicrofluidics
Verified
Journal Article
Open access
PDF file
LBLydia Baldwin
Lydia Baldwin
EJEmily Jones
Emily Jones
AIAlexander Iles
Alexander Iles
SCSimon Carding
Simon Carding
Nicole PammeNicole Pamme
Nicole Pamme
JGJohn Greenman
John Greenman
Despite the large number of microfluidic devices that have been described over the past decade for the study of tissues and organs, few have become widely adopted. There are many reasons for this lack of adoption, primarily that devices are constructed for a single purpose or because they are highly complex and require relatively expensive investment in facilities and training. Here, we describe a microphysiological system (MPS) that is simple to use and provides fluid channels above and below cells, or tissue biopsies, maintained on a disposable, poly(methyl methacrylate), carrier held between polycarbonate outer plates. All other fittings are standard Luer sizes for ease of adoption. The carrier can be coated with cells on both sides to generate membrane barriers, and the devices can be established in series to allow medium to flow from one cell layer to another. Furthermore, the carrier containing cells can be easily removed after treatment on the device and the cells can be visualized or recovered for additional off-chip analysis. A 0.4 μm membrane with cell monolayers proved most effective in maintaining separate fluid flows, allowing apical and basal surfaces to be perfused independently. A panel of different cell lines (Caco-2, HT29-MTX-E12, SH-SY5Y, and HUVEC) were successfully maintained in the MPS for up to 7 days, either alone or on devices connected in series. The presence of tight junctions and mucin was expressed as expected by Caco-2 and HT-29-MTX-E12, with Concanavalin A showing uniform staining. Addition of Annexin V and PI showed viability of these cells to be >80% at 7 days. Bacterial extracellular vesicles (BEVs) produced by Bacteroides thetaiotaomicron and labeled with 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbo-cyanine perchlorate (DiD) were used as a model component of the human colonic microbiota and were visualized translocating from an apical surface containing Caco-2 cells to differentiated SH-SY5Y neuronal cells cultured on the basal surface of connected devices. The newly described MPS can be easily adapted, by changing the carrier to maintain spheroids, pieces, or slices of biopsy tissue and joined in series to study a variety of cell and tissue processes. The cell layers can be made more complex through the addition of multiple cell types and/or different patterning of extracellular matrix and the ability to culture cells adjacent to one another to allow study of cell:cell transfer, e.g., passive or active drug transfer, virus or bacterial entry or BEV uptake and transfer.

Verified
Journal Article
Open access
PDF file
RSRégis Stentz
Régis Stentz
EJEmily Jones
Emily Jones
LGLejla Gul
Lejla Gul
DLDimitrios Latousakis
Dimitrios Latousakis
APAimee Parker
Aimee Parker
SCSimon Carding
Simon Carding
Bacterial extracellular vesicles (BEVs) produced by members of the intestinal microbiota can not only contribute to digestion but also mediate microbe–host cell communication via the transfer of functional biomolecules to mammalian host cells. An unresolved question is which host factors and conditions influence BEV cargo and how they impact host cell function. To address this question, we analysed and compared the proteomes of BEVs released by the major human gastrointestinal tract (GIT) symbiont Bacteroides thetaiotaomicron (Bt) in vivo in fed versus fasted animals using nano-liquid chromatography with tandem mass spectrometry (LC-MSMS). Among the proteins whose abundance was negatively affected by fasting, nine of ten proteins of the serine protease family, including the regulatory protein dipeptidyl peptidase-4 (DPP-4), were significantly decreased in BEVs produced in the GITs of fasted animals. Strikingly, in extracellular vesicles produced by the intestinal epithelia of the same fasted mice, the proteins with the most increased abundance were serine protease inhibitors (serpins). Together, these findings suggest a dynamic interaction between GI bacteria and the host. Additionally, they indicate a regulatory role for the host in determining the balance between bacterial serine proteases and host serpins exported in bacterial and host extracellular vesicles.